Federal Register / Vol. 77, No. 42 / Friday, March 2, 2012 / Notices 12861 

Dated: February 24, 2012. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2012–5016 Filed 3–1–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request 

In compliance with Section 

3506(c)(2)(A) of the Paperwork 

Reduction Act of 1995 concerning 

opportunity for public comment on 

proposed collections of information, the 

Substance Abuse and Mental Health 

Services Administration (SAMHSA) 

will publish periodic summaries of 

proposed projects. To request more 

information on the proposed projects or 

to obtain a copy of the information 

collection plans, call the SAMHSA 

Reports Clearance Officer on (240) 276– 

1243. 

Comments are invited on: (a) Whether 

the proposed collections of information 

are necessary for the proper 

performance of the functions of the 

agency, including whether the 

information shall have practical utility; 

(b) the accuracy of the agency’s estimate 

of the burden of the proposed collection 

of information; (c) ways to enhance the 

quality, utility, and clarity of the 

information to be collected; and (d) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques or 

other forms of information technology. 

Proposed Project: National Mental 

Health Services Survey (N–MHSS) 

(OMB No. 0930–0119)—Revision 

The Substance Abuse and Mental 

Health Services Administration 

(SAMHSA), Center for Behavioral 

Health Statistics and Quality (CBHSQ), 

is requesting approval for a revision to 

the National Mental Health Services 

Survey (N–MHSS) (OMB No. 0930– 

0119), which expires on February 28, 

2013. The N–MHSS provides national 

and state-level data on the number and 

characteristics of mental health 

treatment facilities in the United States. 

An immediate need under N–MHSS 

in 2012 is to update the information 

about facilities on SAMHSA’s online 

Mental Health Facility Locator (see: 

http://store.samhsa.gov/mhlocator), 

which was last updated with 

information from the 2010 N–MHSS. A 

full N–MHSS is anticipated within 

about two years, and a separate request 

for OMB approval will be submitted for 

that collection. However, until then, an 

abbreviated version of the N–MHSS will 

be conducted to collect only the 

information needed to update the 

Locator, such as the facility name and 

address, specific services offered, and 

special client groups served. The data 

on the Locator are becoming outdated 

and need an update method. Other 

fields in the full N–MHSS not needed 

for updating the Locator, such as client 

counts and client demographics, will 

not be collected in the Locator survey. 

In addition to the data collection for 

updating facilities on the Locator, a data 

collection in conjunction with adding 

new facilities to the Locator is being 

requested. Both activities will use the 

same abbreviated N–MHSS–Locator 

instrument. 

This requested revision seeks to 

change the content of the currently 

approved full-scale N–MHSS survey 

instrument into an abbreviated survey 

instrument, henceforth referred to as the 

N–MHSS–Locator, to accommodate two 

related N–MHSS activities: 

(1) Collection of information from the 

full N–MHSS universe of mental health 

treatment facilities during 2012, 2013, 

and 2014. This abbreviated subset of N– 

MHSS data will update and expand 

SAMHSA’s existing online Mental 

Health Facility Locator (see: http:// 

store.samhsa.gov/mhlocator), which 

was last updated with information from 

the 2010 N–MHSS; and 

(2) Collection of information on newly 

identified facilities throughout the year, 

as they are identified, so that new 

facilities can quickly be added to the 

Locator. 

The survey mode for both data 

collection activities will be web with 

telephone follow-up. 

The database resulting from the 2012 

N–MHSS–Locator will be used to 

update SAMHSA’s online Mental 

Health Facility Locator and to produce 

a 2012 compact disk (CD) directory of 

facilities, both for use by consumers and 

service providers. In addition, a data file 

derived from the survey will be used to 

produce an annual report providing 

state and national data on the number 

and types of treatment facilities and 

services. The annual report and a 

public-use data file to be released in 

conjunction with the report will be used 

by researchers, mental health 

professionals, State governments, the 

U.S. Congress, and the general public. 

The following table summarizes the 

estimated response burden for the two 

survey activities: 

ESTIMATED TOTAL RESPONSE BURDEN FOR THE N–MHSS 

Type of respondent Number of 

respondents 

Responses 

per 

respondent 

Average hours 

per response 

Total hour 

burden 

Facilities in annual N–MHSS–Locator universe .............................................. 15,000 1 .42 6,300 

Newly identified facilities 1 ................................................................................ 1,500 1 .42 630 

Total Facilities ........................................................................................... 16,500 ........................ ........................ 6,930 

1 Collection of information on newly identified facilities throughout the year, as they are identified, so that new facilities can quickly be added to 

the Locator. 


tkelley on DSK3SPTVN1PROD with NOTICES
12862 Federal Register / Vol. 77, No. 42 / Friday, March 2, 2012 / Notices 

* The Standards Council of Canada (SCC) voted 

to end its Laboratory Accreditation Program for 

Substance Abuse (LAPSA) effective May 12, 1998. 

Laboratories certified through that program were 

accredited to conduct forensic urine drug testing as 

required by U.S. Department of Transportation 

(DOT) regulations. As of that date, the certification 

of those accredited Canadian laboratories will 

continue under DOT authority. The responsibility 

for conducting quarterly performance testing plus 

periodic on-site inspections of those LAPSAaccredited laboratories was transferred to the U.S. 

HHS, with the HHS’ NLCP contractor continuing to 

have an active role in the performance testing and 

laboratory inspection processes. Other Canadian 

laboratories wishing to be considered for the NLCP 

may apply directly to the NLCP contractor just as 

U.S. laboratories do. 

Upon finding a Canadian laboratory to be 

qualified, HHS will recommend that DOT certify 

the laboratory (Federal Register, July 16, 1996) as 

meeting the minimum standards of the Mandatory 

Guidelines published in the Federal Register on 

April 30, 2010 (75 FR 22809). After receiving DOT 

certification, the laboratory will be included in the 

monthly list of HHS-certified laboratories and 

participate in the NLCP certification maintenance 

program. 

Send comments to Summer King, 

SAMHSA Reports Clearance Officer, 

Room 8–1099, One Choke Cherry Road, 

Rockville, MD 20857 or email a copy to 

summer.king@samhsa.hhs.gov. Written 

comments must be received before 60 

days after the date of the publication in 

the Federal Register. 

Summer King, 

Statistician. 

[FR Doc. 2012–5151 Filed 3–1–12; 8:45 am] 

BILLING CODE 4162–20–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Current List of Laboratories and 

Instrumented Initial Testing Facilities 

Which Meet Minimum Standards To 

Engage in Urine Drug Testing for 

Federal Agencies 

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS. 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services (HHS) notifies Federal 

agencies of the Laboratories and 

Instrumented Initial Testing Facilities 

(IITF) currently certified to meet the 

standards of the Mandatory Guidelines 

for Federal Workplace Drug Testing 

Programs (Mandatory Guidelines). The 

Mandatory Guidelines were first 

published in the Federal Register on 

April 11, 1988 (53 FR 11970), and 

subsequently revised in the Federal 

Register on June 9, 1994 (59 FR 29908); 

September 30, 1997 (62 FR 51118); 

April 13, 2004 (69 FR 19644); November 

25, 2008 (73 FR 71858); December 10, 

2008 (73 FR 75122); and on April 30, 

2010 (75 FR 22809). 

A notice listing all currently certified 

Laboratories and Instrumented Initial 

Testing Facilities (IITF) is published in 

the Federal Register during the first 

week of each month. If any Laboratory/ 

IITF’s certification is suspended or 

revoked, the Laboratory/IITF will be 

omitted from subsequent lists until such 

time as it is restored to full certification 

under the Mandatory Guidelines. 

If any Laboratory/IITF has withdrawn 

from the HHS National Laboratory 

Certification Program (NLCP) during the 

past month, it will be listed at the end 

and will be omitted from the monthly 

listing thereafter. 

This notice is also available on the 

Internet at http:// 

www.workplace.samhsa.gov and http:// 

www.drugfreeworkplace.gov. 

FOR FURTHER INFORMATION CONTACT: Mrs. 

Giselle Hersh, Division of Workplace 

Programs, SAMHSA/CSAP, Room 2– 

1042, One Choke Cherry Road, 

Rockville, Maryland 20857; 240–276– 

2600 (voice), 240–276–2610 (fax). 

SUPPLEMENTARY INFORMATION: The 

Mandatory Guidelines were initially 

developed in accordance with Executive 

Order 12564 and section 503 of Public 

Law 100–71. The ‘‘Mandatory 

Guidelines for Federal Workplace Drug 

Testing Programs’’, as amended in the 

revisions listed above, requires strict 

standards that Laboratories and 

Instrumented Initial Testing Facilities 

(IITF) must meet in order to conduct 

drug and specimen validity tests on 

urine specimens for Federal agencies. 

To become certified, an applicant 

Laboratory/IITF must undergo three 

rounds of performance testing plus an 

on-site inspection. To maintain that 

certification, a Laboratory/IITF must 

participate in a quarterly performance 

testing program plus undergo periodic, 

on-site inspections. 

Laboratories and Instrumented Initial 

Testing Facilities (IITF) in the applicant 

stage of certification are not to be 

considered as meeting the minimum 

requirements described in the HHS 

Mandatory Guidelines. A Laboratory/ 

IITF must have its letter of certification 

from HHS/SAMHSA (formerly: HHS/ 

NIDA) which attests that it has met 

minimum standards. 

In accordance with the Mandatory 

Guidelines dated November 25, 2008 

(73 FR 71858), the following 

Laboratories and Instrumented Initial 

Testing Facilities (IITF) meet the 

minimum standards to conduct drug 

and specimen validity tests on urine 

specimens: 

Instrumented Initial Testing Facilities 

(IITF) 

None. 

Laboratories 

ACL Laboratories, 8901 W. Lincoln 

Ave., West Allis, WI 53227, 414–328– 

7840/800–877–7016, (Formerly: 

Bayshore Clinical Laboratory). 

ACM Medical Laboratory, Inc., 160 

Elmgrove Park, Rochester, NY 14624, 

585–429–2264. 

Advanced Toxicology Network, 3560 

Air Center Cove, Suite 101, Memphis, 

TN 38118, 901–794–5770/888–290– 

1150. 

Aegis Analytical Laboratories, 345 Hill 

Ave., Nashville, TN 37210, 615–255– 

2400, (Formerly: Aegis Sciences 

Corporation, Aegis Analytical 

Laboratories, Inc.). 

Alere Toxicology Services, 1111 Newton 

St., Gretna, LA 70053, 504–361–8989/ 

800–433–3823, (Formerly: Kroll 

Laboratory Specialists, Inc., 

Laboratory Specialists, Inc.). 

Alere Toxicology Services, 450 

Southlake Blvd., Richmond, VA 

23236, 804–378–9130, (Formerly: 

Kroll Laboratory Specialists, Inc., 

Scientific Testing Laboratories, Inc.; 

Kroll Scientific Testing Laboratories, 

Inc.). 

Baptist Medical Center-Toxicology 

Laboratory, 11401 I–30, Little Rock, 

AR 72209–7056, 501–202–2783, 

(Formerly: Forensic Toxicology 

Laboratory Baptist Medical Center). 

Clinical Reference Lab, 8433 Quivira 

Road, Lenexa, KS 66215–2802, 800– 

445–6917. 

Doctors Laboratory, Inc., 2906 Julia 

Drive, Valdosta, GA 31602, 229–671– 

2281. 

DrugScan, Inc., P.O. Box 2969, 1119 

Mearns Road, Warminster, PA 18974, 

215–674–9310. 

ElSohly Laboratories, Inc., 5 Industrial 

Park Drive, Oxford, MS 38655, 662– 

236–2609. 

Gamma-Dynacare Medical 

Laboratories,* A Division of the 

Gamma-Dynacare Laboratory 

Partnership, 245 Pall Mall Street, 

London, ONT, Canada N6A 1P4, 519– 

679–1630. 

Laboratory Corporation of America 

Holdings, 7207 N. Gessner Road, 

Houston, TX 77040, 713–856–8288/ 

800–800–2387. 

Laboratory Corporation of America 

Holdings, 69 First Ave., Raritan, NJ 

08869, 908–526–2400/800–437–4986, 

(Formerly: Roche Biomedical 

Laboratories, Inc.). 

Laboratory Corporation of America 

Holdings, 1904 Alexander Drive, 

Research Triangle Park, NC 27709, 


tkelley on DSK3SPTVN1PROD with NOTICES